Glasdegib

(Daurismo)

Glasdegib

Drug updated on 11/16/2023

Dosage FormTablet (oral; 100 mg, 200 mg)
Drug ClassHedgehog pathway inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • To treat newly-diagnosed acute myeloid leukemia in combination with low-dose cytarabine, in patients ≥ 75 years of age or with comorbidities that preclude use of intensive induction chemotherapy in conjunction with low-dose cytarabine.

Product Monograph / Prescribing Information

Document TitleYearSource
Daurismo (glasdegib) Prescribing Information.2023Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines